Tokyo, Japan

Takeo Kohda



 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015-2016

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Takeo Kohda: Innovator in Medical Science

Introduction

Takeo Kohda is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of medical science, particularly in the development of therapeutic agents for chronic kidney disease and malaria. With a total of three patents to his name, Kohda's work reflects a commitment to improving health outcomes through innovative solutions.

Latest Patents

Kohda's latest patents include a prophylactic agent for chronic kidney disease. This method involves administering an agent containing 5-aminolevulinic acid (ALA) or its derivatives to individuals at risk. The formulation may also include metal-containing compounds, such as sodium ferrous citrate, along with various esters and salts of ALA. Another notable patent is an antimalarial drug that utilizes ALA as an active ingredient. This drug is designed for the prevention and treatment of malaria, showcasing Kohda's dedication to addressing infectious diseases.

Career Highlights

Throughout his career, Takeo Kohda has worked with reputable organizations, including Sbi Pharmaceuticals Co., Ltd. and The University of Tokyo. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Kohda has collaborated with notable colleagues such as Tohru Tanaka and Satofumi Kawata. These partnerships have enhanced his research efforts and facilitated the development of innovative medical solutions.

Conclusion

Takeo Kohda's contributions to medical science through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in the treatment of chronic kidney disease and malaria, ultimately benefiting public health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…